E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Facial and truncal acne vulgaris |
Acnee vulgară pe faţă și trunchi |
|
E.1.1.1 | Medical condition in easily understood language |
Facial and truncal acne vulgaris |
Acnee vulgară pe faţă și trunchi |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000519 |
E.1.2 | Term | Acne vulgaris |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in subjects with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months. |
Obiectivul principal al acestui studiu este de a evalua sigurana pe termen
lung a cremei CB-03-01 1% aplicata de doua ori pe zi pentru o perioada
suplimentara de 9 luni la subiecţii cu acnee vulgara care au participat la
studiile pivot de Faza 3, pentru un total de pâna la maxim 12 luni de
tratament. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject must have been enrolled in one of the Phase 3 pivotal studies (CB-03-01/25 and CB-03-01/26), completed the assigned
treatment regimen without any material non-compliance with study requirements or test article dosing (compliance ≥80%), and
completed the final study visit (Visit 4-Pivotal).
2. Subject agrees to treat his/her facial acne and truncal acne (if designated by investigator AND desired by subject) during the
nine month study period per protocol. Note: Subjects who are clear (IGA=0) at Visit 4-Pivotal are also eligible for this study.
3. Females must be post-menopausal1, surgically sterile2, or using highly effective birth control methods.3,4 Women of
childbearing potential (WOCBP)5 must have a negative urine pregnancy test (UPT) at Visit 4-LTF (or Visit 4-Pivotal, if the visits
occur on the same day).
4. Subject has provided written informed consent/assent. A subject under 18 years of age must provide written informed assent
and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must
provide informed consent for the subject. If a subject becomes 18 years of age during the study, the subject must provide written
informed consent at that time to continue study participation.
5. Subject is willing to comply with study instructions and return to the clinic for required visits.
during the study, the subject must provide written informed consent at
that time to continue study participation.
3. Subject has an Investigator’s Global Assessment (IGA) score of 3 or 4 [0
(clear) to 4 (severe) scale].
4. Subject has facial acne vulgaris, which can include the nose, with at least
30 to a maximum of 75 inflammatory lesions (papules, pustules, and
nodules) and 30 to a maximum of 100 non-inflammatory lesions (open
and closed comedones).
5. Subject and parent/guardian (if applicable) are willing to comply with
study instructions and return to the clinic for required visits.
6. Subject has used the same type and brand of make-up, other facial
products (exclusive of RX/OTC acne cleansers) and hair products (e.g.,
shampoo, gel, hair spray, mousse, etc.) for at least one (1) month prior to
the Baseline Visit and agrees to continue his/her other general skin and
hair care products and regimen for the entire study. |
1. Trebuie sa fi fost înrolat în unul dintre studiile pivot de Faza 3 [CB-03-
01/25 si CB-03-01/26], sa fi finalizat regimul de tratament alocat fara
abateri semnificative de la cerinţele studiului sau de la dozarea
produsului investigat (complianţa terapeutica 80%) si sa fi încheiat
vizita finala a studiului (Vizita 4-Pivot).
2. Este de acord sa-si trateze acneea faciala si acneea de la nivelul
trunchiului (la indicaţia investigatorului SI dorinţa subiectului) pe
durata perioadei de 9 luni a studiului conform protocolului. Nota: si
subiecţii care nu mai prezinta acnee (scor EGI=0) la Vizita 4-Studiul
pivot sunt de asemenea eligibili pentru prezentul studiu.
3. Femeile trebuie sa fie în post-menopauza1, sterile în urma unei
intervenţii chirurgicale2 sau sa foloseasca metode sigure de
contracepţie.3,4 Femeile la vârsta fertila5 trebuie sa aiba un rezultat
negativ la testul de sarcina cu urina de la Vizita 4-Studiul LTF (Long-
Term Follow-Up - de urmarire pe termen lung) (sau Vizita 4-Studiul
Pivot în cazul în care vizitele au loc în aceeasi zi).
4. Sa-si dea acordul/consimţamântul informat verbal si în scris. Subiecţii
sub 18 ani trebuie sa-si dea acordul informat în scris si sa fie însoţiţi de
un parinte sau de tutorele legal în momentul semnarii
acordului/consimţamântului. Parintele sau tutorele legal trebuie sa
acorde consimţamântul informat pentru subiect. În cazul în care
subiectul împlineste 18 ani în timpul studiului, acesta trebuie sa-si dea
consimţamântul informat în scris în momentul respectiv pentru a
participa în continuare la studiu.
5. Sa fie dispus sa respecte instrucţiunile studiului si sa se întoarca la
clinica pentru vizitele necesare. |
|
E.4 | Principal exclusion criteria |
1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
2. Subject has any skin pathology or condition that could interfere with the safety evaluation of the test products or requires the
use of interfering topical or systemic therapy (see Section 8.1: Prohibited Medications and Therapies).
3. Subject has any condition which, in the investigator’s opinion, would make it unsafe or unsuitable for the subject to participate
in this research study.
4. Subject plans to use any other investigational drug or device during participation in this study.
5. Subject, and parent/guardian if required, is unable to communicate or cooperate with the investigator due to language
problems, poor mental development, or impaired cerebral function.
6. Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subject who
is unable to return for scheduled follow-up visits.
7. Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test article.
8. Subject is or plans to use any topical anti-acne preparations (excluding CB-03-01 cream) or procedures on the face (or trunk, if
applicable) or any systemic anti-acne medications (as detailed in Section 8.1: Prohibited Medications and Therapies) during the
study. |
1. Este o femeie însarcinata, alapteaza sau planuieste sa ramâna
însarcinata în timpul studiului.
2. Subiectul are orice patologie sau condiţie a pielii care ar putea sa
interfereze cu evaluarea produselor investigate sau necesita folosirea
unui tratament topic sau sistemic interferent (a se vedea Secţiunea 8.1 -
Medicaţii si proceduri interzise).
3. Subiectul prezinta orice condiţie de sanatate care, dupa parerea
investigatorului, face ca participarea sa la acest studiu de cercetare sa
fie riscanta sau nepotrivita pentru el.
4. Subiectul planuieste sa foloseasca orice alt medicament sau dispozitiv
experimental în timpul participarii sale la acest studiu.
5. Subiectul si parintele/tutorele (daca este cazul) nu sunt în masura sa
comunice sau sa coopereze cu investigatorul din cauza problemelor
legate de limba, a unei slabe dezvoltari mentale sau a unei funcţii
cerebrale deficitare.
6. Subiectul nu prezinta încredere pentru studiu, inclusiv subiecţii care
consuma cantitaţi excesive de alcol sau fac abuz de droguri, sau
subiecţii care nu se pot întoarce la clinica pentru a se supune la vizitele
de control programate.
7. Subiectul are hipersensibilitate cunoscuta sau a manifestat anterior o
reacţie alergica la oricare dintre componentele active sau inactive ale
produsului testat.
8. Subiectul foloseste sau planuieste sa foloseasca orice procedura sau
preparat antiacneic topic (excluzând crema CB-03-01) pe faţa (sau pe
trunchi, daca este cazul) sau orice medicaţie antiacneica sistemica
(dupa cum este detaliat în Secţiunea 8.1: Medicaţii si terapii interzise)
în timpul studiului. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Incidence of any local and systemic treatment emergent AEs (TEAEs).
•Number of subjects with presence (and severity) of each individual LSR (Local Skin Reaction) (telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus) for each treatment area, as applicable, at each time point collected (Baseline, and LTF-Months 1, 3, 6, and 9, and any Unscheduled Visits).
•UPT results in all WOCBP at Baseline, LTF-Month 6, and EOS.
|
• Incidenţa oricarui eveniment advers local si sistemic provocat de tratament.
• Numarul subiecţilor care prezinta fiecare reacţie cutanta locala în parte si gravitatea acesteia (telangiectasia, atrofie a pielii, striae rubrae, eritem, edem, descuamare/uscaciune, senzaţie de înţepatura/arsura si prurit) pentru fiecare zona de tratament, dupa caz, colectate la fiecare punct temporal (Vizita Iniţiala si Lunile 1, 3, 6 si 9 si orice Vizita neprogramata din Studiul LTF).
• Rezultatele testului de sarcina cu urina la toate femeile aflate la vârsta fertila de la Vizita Iniţiala, Luna 6-Studiul LTF si Vizita EOS. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
during the study |
Ȋn timpul studiului |
|
E.5.2 | Secondary end point(s) |
• Number of subjects with each IGA (Investigator’s Global Assessment, IGA) severity score for each treatment area, as applicable, at each time point collected |
• Numarul subiecţilor cu fiecare scor de severitate pe scala EGI pentru fiecare zona de tratament, dupa caz, colectate la fiecare
punct temporal |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline and LTF-Months 1, 3, 6, and 9 |
Vizita Iniţiala si Lunile LTF 1, 3, 6 si 9 din Studiul LTF |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 38 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |